mechanism of action of glp 1 agonist Current Insights, Advantages and Challenges Small Molecule Glucagon-like Peptide Receptor Agonists: A Scoping Review Mechanisms of Action and Therapeutic
Description
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
doi: 10.3390/biomedicines9101360
Current Clinical Pharmacology
Preliminary Phase I trials have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo
Studying glycemic control as a primary endpoint
